A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

The health ministry on Monday granted full approval to lecanemab, the much-hyped drug for Alzheimer's disease, but experts point out there are big challenges ahead, particularly on how to control ...

Lecanemab, on the other hand, is designed to slow the development of Alzheimer’s by removing amyloid beta. The medication is administered once every other week through an intravenous drip.

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for use on the NHS. Here is what we know so far about this ...